Published: 08/20/2026 | Author: Terri

Overdose deaths in the United States fell sharply in 2024, and researchers are still working out why. A peer-reviewed analysis published in June offers a careful answer that matters for anyone navigating opioid addiction treatment right now. It concludes that no single intervention explains the decline, and no single intervention sustains recovery either.

The narrative review appeared in Current Addiction Reports on June 23, authored by Wei Hao of Central South University in Changsha, China, Peter Jackson of the University of Vermont Larner College of Medicine, and Gavin Bart of the University of Minnesota Medical School and Hennepin Healthcare. It is open access.

The authors compared public health responses in the United States and China across four areas: demand reduction, harm reduction, supply control, and coordination between agencies. They state plainly that the comparison is not intended to identify a superior national model.

The Opioid Crisis by the Numbers

Provisional CDC data cited in the review show drug overdose deaths in the United States dropped roughly 27 percent in 2024 compared with 2023. That is a substantial improvement. It is also incomplete progress, because the review notes rates remain well above where they stood before fentanyl saturated the illicit supply.

The review also describes what researchers call a fourth wave of the crisis, marked by the convergence of illicit fentanyl and stimulant use. That combination complicates both clinical care and policy, because a person may be exposed to two very different drug classes in a single product.

On what drove the decline, the authors are deliberately cautious. Disruption of illicit fentanyl supply chains, particularly precursor chemical controls, may have contributed.

So may expanded treatment access and harm reduction. The review’s position is that these factors are closely linked and that supply control alone does not account for the change.

Understanding Opioids and Naloxone

Opioids are a drug class that acts on mu-opioid receptors to relieve pain and produce sedation and euphoria. Fentanyl is a synthetic opioid many times more potent than heroin, which is why small variations in an illicit dose can be fatal.

Naloxone, sold as Narcan, is an opioid antagonist that displaces opioids from those receptors and can reverse an overdose within minutes. It does not work on non-opioid drugs, and because fentanyl is long acting relative to a single naloxone dose, more than one dose is sometimes required and emergency care is still needed.

What the Review Found About Treatment in the United States

The authors credit substantial American progress in evidence-based care for opioid addiction. Methadone, buprenorphine, and extended-release naltrexone are described as widely recognized standard of care, with addiction medicine and addiction psychiatry established as specialty fields.

They also point to access innovations including office-based buprenorphine prescribing, starting outpatient treatment in emergency departments, integrating addiction care into primary care, and low-threshold programs built on a no wrong door principle.

The gap they identify is continuity, not availability of good treatment. Many people receive effective care during hospitalization, incarceration, or an acute crisis, then hit service gaps, insurance disruption, unstable housing, and thin community support on the way back out. The review links those transitions to return to use and to reentry into emergency or correctional systems.

That finding is worth sitting with if you are planning your own care or a family member’s. The riskiest moment is often not the start of treatment. It is the handoff.

What the Review Found About China

The authors report sustained declines in China across several indicators, including seven consecutive years of reductions in the number of recorded drug users, along with reductions in newly identified users and drug-related criminal cases.

They describe a system linking acute withdrawal management, rehabilitation, case management, family intervention, employment assistance, and long-term follow-up, referred to as a seamless connection model.

They also note limits, including difficulty implementing it in rural areas, and new challenges from non-medical use of prescription medicines such as pregabalin and tramadol. On supply, the review notes China adopted class-based scheduling of fentanyl-related substances in 2019.

The authors treat these as differences in governance structure and legal tradition rather than evidence that one system outperforms the other. They also state that assigning responsibility for synthetic opioid supply to a single country is analytically insufficient, and that coordinated regulation across manufacturing, trade, and customs systems is what supply control actually requires.

Harm Reduction and Treatment

The review places harm reduction as a core component of current opioid policy rather than an alternative to treatment. It names overdose education, naloxone distribution, low-threshold treatment programs, drug checking strips, and syringe service programs as significant public health interventions when paired with medication for opioid use disorder. It also notes that permissible harm reduction measures differ from state to state, so what is available near you depends on local law.

Finding Help for Opioid Addiction

The review’s practical takeaway for individuals is that recovery is better supported when medical treatment, peer community, and social stability are working at the same time rather than in sequence.

Medication for opioid use disorder is the clinical foundation. Methadone is dispensed through opioid treatment programs, buprenorphine can be prescribed in office-based settings, and extended-release naltrexone is an option after a period without opioids. Peer recovery fills the continuity gap the review describes.

Narcotics Anonymous meetings are free, require no insurance, and run daily in most metropolitan areas and virtually everywhere online. Searching NA meetings near me by zip code is usually faster than searching by city, since meeting lists are organized by local service committee.

Narcotics.com is not affiliated with Narcotics Anonymous. NA is a nonprofit fellowship and does not endorse, finance, or align itself with any outside organization, publication, or directory.

Narcotics.com lists opioid treatment programs and NA meeting resources nationwide. Call 800-934-1582(Sponsored) to get connected to treatment options at no cost.